We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Serodiagnostic Test Developed for Human Leptospirosis

By LabMedica International staff writers
Posted on 11 Jul 2013
A vertical flow diagnostic test has been developed for the serodiagnosis of human leptospirosis, which is difficult to diagnose because of nonspecific symptoms and concurrent other endemic febrile diseases.

Scientists at the Pasteur Institute of New Caledonia (Noumea, New Caledonia) working with their colleagues at the Pasteur Institute (Paris, France) tested 187 confirmed leptospirosis cases sera. There were 120 from New Caledonia, 38 from mainland France, 29 from French West Indies. Whole killed Leptospira fainei cells were used as the antigen for the test line and purified human immunoglobulin M (IgM) as the control line. The mobile phase was made of gold particles conjugated with goat anti-human IgM. The Microscopic Agglutination Test (MAT) was used as the gold standard with a cut-off titer of equal to or greater than 1:400.

Image: Vertical Flow Rapid Diagnostic Test for Leptospirosis (Photo courtesy of Pasteur Institute of New Caledonia).
Image: Vertical Flow Rapid Diagnostic Test for Leptospirosis (Photo courtesy of Pasteur Institute of New Caledonia).

Out of the 187 gold standard positive sera tested, 168 were RDT positive, including 15 RDT with a test line intensity graded as weak. Out of the 221 MAT-negative sera tested, 207 were RDT negative. All 14 RDT positive sera were graded weak and originated from nine healthy blood donors and five patients positive for anti-dengue virus IgM. The RDT sensitivity was 89.8% and the specificity 93.7%. This RDT had satisfactory reproducibility, repeatability, thermal tolerance, and shelf life. The comparison with MAT evidenced the earliness of the RDT to detect seroconversion. The Vertical Flow RDT developed displayed good diagnostic performances when compared with a lateral flow RDT (Leptocheck, Zephyr Biomedicals; Goa, India).

The authors concluded that because leptospirosis is endemic in New Caledonia and French West Indies, they considered both a MAT titer of 1:400 as a gold standard and a 1/400 dilution of the serum for the Vertical Flow RDT for evaluation. They wrote that it is highly probable that the use of a lower dilution of 1/200 or 1/100 would result in both an increased sensitivity and a decreased specificity. The use of the Vertical Flow RDT as an initial screen for leptospiral infections would still allow facilitating the difficult differential diagnosis of leptospirosis. The study was published on June 27, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Pasteur Institute of New Caledonia
Pasteur Institute
Zephyr Biomedicals



Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
Histamine ELISA
Histamine ELISA
New
Newborn Screening Test
NeoMass AAAC 3.0

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients